Orrick advised Catalyst Biosciences, Inc. on the deal. South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. announced its acquisition of the F351 program, a next-generation fibrosis drug,...
Catalyst Biosciences’ Reverse Merger with GNI Group
Catalyst Biosciences’ $60 Million Sale of Complement Portfolio
Orrick advised Catalyst Biosciences, Inc. on the deal. South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced the sale of its complement asset portfolio for...